| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Net revenue | ||||||||
26,458 | 23,604 | 21,091 | 17,925 | 15,174 | 13,017 | 0 | 0 | 0 |
Cost of revenue | ||||||||
10,308 | 9,741 | 9,470 | 8,388 | 7,791 | 7,283 | 0 | 0 | 0 |
Gross profit | ||||||||
16,150 | 13,863 | 11,621 | 9,537 | 7,383 | 5,734 | 0 | 0 | 0 |
Operating expenses: | ||||||||
Research, development and clinical trials | ||||||||
22,213 | 19,870 | 17,094 | 15,427 | 14,073 | 13,656 | 0 | 0 | 0 |
Selling, general and administrative | ||||||||
25,595 | 23,596 | 21,797 | 18,077 | 14,728 | 12,315 | 0 | 0 | 0 |
Total operating expenses | ||||||||
47,808 | 43,466 | 38,891 | 33,504 | 28,801 | 25,971 | 0 | 0 | 0 |
Loss from operations | ||||||||
-31,658 | -29,603 | -27,270 | -23,967 | -21,418 | -20,237 | 0 | 0 | 0 |
Other income (expense): | ||||||||
Interest expense | ||||||||
4,302 | 4,353 | 4,363 | 4,355 | 3,555 | 2,720 | 0 | 0 | 0 |
Change in fair value of preferred stock warrant liability | ||||||||
614 | 341 | 463 | 646 | 242 | 545 | 0 | 0 | 0 |
Other income (expense), net | ||||||||
1,110 | 790 | 139 | 184 | -491 | -213 | 0 | 0 | 0 |
Total other expense, net | ||||||||
-3,806 | -3,904 | -4,687 | -4,817 | -4,288 | -3,478 | 0 | 0 | 0 |
Loss before income taxes | ||||||||
-35,464 | -33,507 | -31,957 | -28,784 | -25,706 | -23,715 | 0 | 0 | 0 |
Provision for income taxes | ||||||||
40 | 40 | 48 | 46 | 44 | 41 | 0 | 0 | 0 |
Net loss | ||||||||
-35,504 | -33,547 | -32,005 | -28,830 | -25,750 | -23,756 | 0 | 0 | 0 |
Net loss per share attributable to common stockholders, basic and diluted | ||||||||
-0.42 | 3.59 | -0.39 | -0.70 | -4.86 | -8.84 | -3.73 | -1.30 | -3.61 |
Weighted average common shares outstanding, basic and diluted | ||||||||
21,221 | 21,135 | 21,131 | 13,133 | 1,418 | -1,978 | 1,368 | 4,686 | 1,358 |